Exposure to both radiation and chemotherapy increases the risk of Barrett's and multilayered epithelium

Shields, Helen M.; Recht, Abram; Wang, Helen H.
October 2009
Digestive Diseases & Sciences;Oct2009, Vol. 54 Issue 10, p2143
Academic Journal
journal article
The relationship between radiation and/or chemotherapy and the development of Barrett's and/or multilayered epithelium has not been investigated before. We ascertained a group of patients exposed to radiation and/or chemotherapy and an unexposed group to compare the prevalence rates of Barrett's epithelium and multilayered epithelium at the time of endoscopy in these two groups. Barrett's epithelium was found in ten of the 19 (53%) exposed patients, compared to eight of 38 (21%) unexposed subjects (P = 0.02). Six of 19 (32%) exposed patients had multilayered epithelium, compared to four of 38 (11%) unexposed subjects (P = 0.06). Twelve of the 19 exposed patients (63%) had either Barrett's or multilayered epithelium, in contrast to ten of 38 (26%) unexposed subjects (P = 0.01). Those with exposure to both chemotherapy and radiation had a significant increase in the risk for Barrett's and/or multilayered epithelium (P = 0.003). This study suggests a relationship between exposure to a combination of radiation and chemotherapy and the development of Barrett's and/or multilayered epithelium.


Related Articles

  • Ultrathin Esophagoscopy in Screening for Barrett's Esophagus at a Veterans Administration Hospital: Easy Access Does Not Lead to Referrals. Atkinson, Matt; Das, Ananya; Faulx, Ashley; Kinnard, Margaret; Falck-Ytter, Yngve; Chak, Amitabh // American Journal of Gastroenterology;Jan2008, Vol. 103 Issue 1, p92 

    OBJECTIVE: Unsedated, ultrathin esophagoscopy has been shown to be tolerable, safe, and accurate. Survey data have suggested that accessibility of unsedated esophagoscopy would increase referrals for Barrett's esophagus (BE) screening. Our purpose was to evaluate primary-care physician referrals...

  • The value of high-definition plus endoscopy with i-Scan in diagnosis of Barrett's esophagus. ZOU Bai-cang; DONG Lei; CHEN Fen-rong; ZHAO Ju-hui; SHI Hai-tao; ZHAO Gang; JIA Miao // Journal of Xi'an Jiaotong University (Medical Sciences);Sep2013, Vol. 34 Issue 5, preceding p629 

    Objective To study the significance of high-definition plus (HD+) endoscopy with i-Scan (EPK-i endoscopy) in diagnosis of Barrett' s esophagus (BE). Methods We counted the patients diagnosed as BE by EPK-i endoscopy in 1806 subjects and by white light endoscopy in 1784 subjects in our hospital....

  • Columnar-lined Esophagus: Its Prevalence and Predictors in Patients With Gastroesophageal Reflux Disease. Gwang Ha Kim // Journal of Neurogastroenterology & Motility;Apr2013, Vol. 19 Issue 2, p261 

    The article discusses prevalence of Barrett's esophagus in patients with gastroesophageal reflux disease. It mentions that in Barrett's esophagus normal stratified squamous epithelium is replaced by metaplastic columnar epithelium. It informs that in Great Britain and Asia Barrett's esophagus is...

  • DFMO may offer chemopreventive effect in Barrett's esophagus and dysplasia.  // Hem/Onc Today;12/10/2008, Vol. 9 Issue 22, p20 

    The article reports on the findings of a study which showed the effect of difluoromethylornithine (DFMO) on Barrett's esophagus and mucosal dysplasia. Results were presented by Frank Sinicrope of the Mayo Clinic who showed that treatment with DFMO was linked to suppressed mucosal putrescine...

  • Radiofrequency Ablation of Barrett’s Esophagus. Watson, Thomas J. // Journal of Gastrointestinal Surgery;Feb2010 Supplement 1, Vol. 14, p88 

    Barrett’s esophagus (BE) is known to be due to chronic gastroesophageal reflux disease and is a precursor of esophageal adenocarcinoma. The ability to eliminate BE is appealing, given the neoplastic potential of this condition and the continued increase in incidence of adenocarcinoma...

  • A pilot pharmacokinetic study of oral azacitidine. Garcia-Manero, G.; Stoltz, M. L.; Ward, M. R.; Kantarjian, H.; Sharma, S. // Leukemia (08876924);Sep2008, Vol. 22 Issue 9, p1680 

    Azacitidine is a pyrimidine nucleoside analog of cytidine with hypomethylating and antileukemia activity. Azacitidine has been shown to have survival benefits in patients with high-risk myelodysplastic syndrome (MDS), and has activity in the treatment of acute myelogenous leukemia (AML). It is...

  • Long-term chronic opioid therapy discontinuation rates from the TROUP study. Martin, Bradley; Fan, Ming-Yu; Edlund, Mark; DeVries, Andrea; Braden, Jennifer; Sullivan, Mark; Martin, Bradley C; Edlund, Mark J; Braden, Jennifer Brennan; Sullivan, Mark D // JGIM: Journal of General Internal Medicine;Dec2011, Vol. 26 Issue 12, p1450 

    Objective: To report chronic opioid therapy discontinuation rates after five years and identify factors associated with discontinuation.Methods: Medical and pharmacy claims records from January 2000 through December 2005 from a national private health network...

  • Cytosponge is alternative to endoscopy. CZYZEWSKI, ANDREW // Engineer (00137758);8/15/2011, Vol. 296 Issue 7822, p7 

    The article offers information on the new device called cytosponge which is used for detecting Barrett's oesophagus and promises to be around 10 times cheaper and considerably less invasive than standard endoscopy.

  • Unsedated Transnasal Endoscopy (uTNE): Not Quite Ready to Replace Sedated Esophagogastroduodenoscopy (sEGD). Syed, Aslam; Kyprianou, Annette // American Journal of Gastroenterology;Jun2015, Vol. 110 Issue 6, p936 

    A letter to the editor is presented in response to the article "A Randomized Comparative Effectiveness Trial of Novel Endoscopic Techniques and Approaches for Barrett's Esophagus Screening in the Community" by S. S. Sami published in the journal in 2015.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics